Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?

Medical Care

Volumn 47, Issue 3, 2009, Pages 319-325

  Shrank, William H ^a,c   Cadarette, Suzanne M ^a   Cox, Emily ^b   Fischer, Michael A ^a   Mehta, Jyotsna ^a   Brookhart, Alan M ^a   Avorn, Jerry ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Express Scripts   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Communication; Generic; Medications; Perceptions; Utilization

Indexed keywords

GENERIC DRUG;

ADULT; ARTICLE; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; INTERPERSONAL COMMUNICATION; PATIENT ATTITUDE; PHARMACY; PHYSICIAN; PRESCRIPTION; QUESTIONNAIRE; SOCIOECONOMICS; AGED; DOCTOR PATIENT RELATION; EPIDEMIOLOGY; EVALUATION; FACTORIAL ANALYSIS; FEMALE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERCEPTION; PSYCHOLOGICAL ASPECT; SAFETY; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; COMMUNICATION; DRUG COSTS; DRUGS, GENERIC; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEALTH CARE SURVEYS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; PERCEPTION; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; SAFETY; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 61849090795     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31818af850     Document Type: Article

References (39)

1. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing." N Engl J Med. 1983;308:1457-1463.
2. Fretheim A, Aaserud M, Oxman AD. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice. PLoS Med. 2006;3:e216.
3. Scott AB, Culley EJ, O'Donnell J. Effects of a physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization. J Manag Care Pharm. 2007;13:412-419.
4. Tootelian DH, Royer J, Johnson RC. Providing incentives to control health care costs and remain competitive in the marketplace: a pilot study. Health Mark Q. 1997;15:87-99.
5. Andersson K, Bergström G, Petzold MG, et al. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Health Policy. 2007;81:376-384.
6. Johnsrud M, Lawson KA, Shepherd MD. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans. J Manag Care Pharm. 2007;2:122-134.
7. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346:822-829.
8. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351:2187-2194.
9. Rector TS, Finch MD, Danzon PM, et al. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41:398-406.
10. Kesselheim AS, Misono AS, Lee JL, et al. The clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514-2526.
11. O'Malley AJ, Frank RG, Kaddis A, et al. Impact of alternative interventions on changes in generic dispensing rates. Health Serv Res. 2006;41:1876-1894.
12. Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care. 2007;45:109-115.
13. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662-674.
14. Shrank WH, Stedman M, Ettner SL, et al. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J Gen Intern Med. 2007;9:1298-1304.
15. Federman AD, Halm EA, Zhu C, et al. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;10:611-618.
16. Bearden WO, Mason JB. Consumer-perceived risk and attitudes toward genetically prescribed drugs. J Appl Psychol. 1978;63:741-746.
17. Carroll NV, Wolfgang AP, Kotzan JA, et al. Consumer attitudes and actions towards generic drugs. J Pharm Mark Manage. 1988;2:87-89.
18. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash). 2000;40:378-383.
19. Gaither CA, Kirking DM, Ascione FJ, et al. Consumers' views on generic medications. J Am Pharm Assoc. 2001;41:729-736.
20. Sansgiry SS, Bhosle M, Pope N. Consumer perceptions regarding generic drug substitution: an exploratory study. J Pharm Mark Manage. 2005;17:77-81.
21. Rosenstock I. Historical origins of the health belief model. Health Educ Monographs. 1974;2:4.
22. Nunnally JC, Bernstein IH. Psychometric Theory. Toronto, ON: McGraw-Hill, Inc; 1994.
23. Hair JF, Anderson RE, Tatham RL, et al. Multivariate Data Analysis. Upper Saddle River, NJ: Prentice Hall; 1998.
24. Loehlin JC. Latent Variable Models: An Introduction to Factor, Path, and Structural Analysis. Hillsdale, NJ: Lawrence Erlbaum Associates; 1992.
25. McHorney CA, Ware JE, Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Test of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
26. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585-598.
27. Tarn DM, Heritage J, Paterniti DA, et al. Physician communication when prescribing new medications. Arch Intern Med. 2006;166:1855-1862.
28. Svarstad BL, Bultman DC, Mount JK. Patient counseling provided in community pharmacies: effects of state regulation, pharmacist age, and busyness. J Am Pharm Assoc. 2004;44:22-29.
29. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communi-cation about out-of-pocket costs. JAMA. 2003;290:953-958.
30. Shrank WH, Joseph GJ, Choudhry NK, et al. Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or the population matter most? Am J Manag Care. 2006;12:545-551.
31. Shrank WH, Fox SA, Kirk A, et al. The effect of pharmacy benefit design on patient-physician communication about costs. J Gen Intern Med. 2006;21:334-339.
32. Kathleen Jaeger. Generic Pharmaceutical Association's (GPhA) Annual Report for 2006. Available at: http://www.gphaonline.org/AM/Template. cfin?Section=Home§ion=Press_kit&template=/CM/ContentDisplay. cfm&ContentFileID=193. Accessed Februrary 20, 2008.
33. Kaiser Family Foundation and Health Research and Educational Trust. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/ 3057_06.pdf. Accessed December 5, 2007.
34. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med. 2006;166:332-337.
35. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293:1995-2002. Erratum in: JAMA. 2005;294:2436.
36. Mangione-Smith R, McGlynn EA, Elliott MN, et al. The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior. Pediatrics. 1999;103:711-718.
37. Shrank WH, Cox E, Fischer MA, et al. Patient perceptions of generic medications. Health Aff. In press.
38. Cox E. Express Scripts Drug Trends Report. 2007 Available at: http://www.express-scripts.com/mdustryresearclVrndustryreports/aYugtrendreport/ 2007/. Accessed April 22, 2008.
39. Shrank WH, Young HN, Ettner SL, et al. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a Physician Leadership Survey. Am J Manag Care. 2005;11:16-22.